medwireNews: The platelet function substudy of the TRILOGY-ACS trial shows that there is no significant difference between prasugrel and clopidogrel in cardiovascular (CV) mortality, myocardial infarction (MI), or stroke outcomes. Moreover, there was no significant association between platelet ...
(STEMI) guidelines, which include recommendations for the use of the antiplatelet agents ticagrelor, prasugrel, and clopidogrel, based in part on results from the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel–Thrombolysis In Myocardial Infarction (...
BackgroundIn the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial of patients with non-ST-segment elevation acute coronary syndrome managed medically without revascularization, treated with prasugrel versus clopidogrel for less than...
Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: Insights from the TRILOGY ACS trialKeywords acute coronary syndromeADP receptor antagonistoutcomeBackground: Certain alleles of the CYP2C19 gene are associated with higher platelet reactivity and increased ischemic events amo...
A randomized trial of prasugrel versus clopidogrel in patients with 31 32 high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation 33 34 of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing 35 36 Elective...
PrasugrelACS-NSTEMIAnti-platelet agentsBackground: Patients with high post-loading platelet aggregation (PPA) are at increased risk of stent thrombosis and death after primary percutaneous coronary intervention (pPCI). The objective of the present trial was to examine whether high PPA is associated ...